
==== Front
Med Sci Monit
Med Sci Monit
Medical Science Monitor
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
1234-1010
1643-3750
International Scientific Literature, Inc.

39217431
10.12659/MSM.946343
946343
Editorial
Editorial: Reasons for Increasing Global Concerns for the Spread of Mpox
Parums Dinah V. MD, PhD
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA
e-mail: dinah.v.parums@isi-science.com
2024
01 8 2024
28 8 2024
30 e946343-1e946343-2
28 8 2024
28 8 2024
© Med Sci Monit, 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
On August 14, 2024, the Director General of the World Health Organization (WHO) declared that the increasing outbreaks of mpox (formerly monkeypox) should be regarded as an international public health emergency due to the growing number of cases in endemic and non-endemic geographical areas, and increasing disease severity. The latest update from the WHO and the alerts given regarding the status of mpox follows an upsurge in the incidence and severity of mpox in the Democratic Republic of the Congo (DRC) and an increasing number of African countries, with spread to other continents and countries This Editorial aims to provide an update on the current status of mpox and includes reasons for the increasing global concerns for the spread of the mpox virus (MPXV).

Mpox
Monkeypox
Orthopoxvirus
Editorial
==== Body
pmcOn August 14, 2024, the Director General of the World Health Organization (WHO) declared that the increasing outbreaks of mpox (formerly monkeypox) should be regarded as an international public health emergency due to the growing number of cases in endemic and non-endemic geographical areas, and increasing disease severity [1–3]. Two years previously, outbreaks of mpox became so high that on July 23, 2022, the WHO declared mpox as a Public Health Emergency of International Concern (PHEIC) [4,5]. However, almost a year later, on May 11, 2003, the WHO declared the end of the global public health emergency for mpox [6,7].

The mpox virus (MPXV), or Orthopoxvirus monkeypox, is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family, which also includes several animal poxviruses, cowpox virus, vaccinia virus, and variola virus [8,9]. Infection with MPXV causes a disease similar to smallpox [5,6]. MPXV consists of two genetically distinct clades, clade I (formerly the Congo Basin/Central African clade), and clade II (formerly the West African clade [4,9]. The genetic differences between the genomes of the two MPXV clades and the ongoing development of new variants could explain the recent increase in spread, epidemiology, and pathogenesis, as Clade I is associated with more severe disease, with increased mortality rates [9–11].

An important feature in the pathogenesis of viruses of the genus Orthopoxvirus is their known long-lasting stability in the environment [12]. Viable MPXV can be detected on surfaces for at least 15 days after contamination and are less sensitive to organic disinfectants when compared to other enveloped viruses [12].

The latest update from the WHO and the alerts given regarding the PHEIC status of mpox follows an upsurge of mpox in the Democratic Republic of the Congo (DRC) and an increasing number of African countries, with spread to other continents and countries [1]. The spread of a new sexually transmissible strain of the MPXV and new clades and virus variants may be explained by inadequate infection surveillance during 2022 and 2023 [2]. Now, mpox infection should be regarded as an emergency for Africa and the rest of the world [1,2].

Although mpox has been endemic in West and Central Africa it came to the attention of the World Health Organization in 2022 when laboratory-confirmed cases were reported in 50 non-endemic countries, mainly in adults, and mainly in Europe [4,5]. In the US, the Centers for Disease Control and Prevention (CDC) identified an outbreak of mpox in May 2022, with 99% of cases in adult men, 94% reported cases being due to male-to-male sexual contact or intimate contact three weeks before symptoms of infection [13]. Also, in 2022, 46% of infected patients reported one or more genital lesions, and in the US, 41% of adult patients also had HIV infection [13]. Therefore, initial public health measures in the US aimed to prioritize specific adult male demographic groups for infection prevention and testing [13]. By August 4, 2022, the Department of Health and Human Services (HHS) declared the mpox outbreak a public health emergency in the US [13]. On August 22, 2022, the European Centre for Disease Prevention and Control (ECDC) rapidly published a factsheet for health professionals on the prevention and management of mpox [14].

Because MPXV is crossing geographical boundaries and has varied and unpredictable transmission patterns, it is urgently needed to contain this infection before it reaches pandemic status (1,3). Public health measures require infection surveillance, rapid diagnosis, contact tracing, patient isolation and management, and vaccination [15]. The three main approved MPXV vaccines are ACAM2000, MVA-BN, and LC16, all recommended by the WHO [1,15]. The WHO has now provided vaccination guidance for those in contact with infected people or those in current non-endemic areas who may be at risk for contracting pox when traveling [1,15]. However, mass vaccination is still not currently recommended, and in many countries, vaccine availability is limited [1,2].

Conclusions

The current status of the global spread of MPXV and the increasing number and severity of cases of mpox in African countries has occurred due to a lack of infection surveillance and control and a lack of availability of approved vaccines. Urgent public health measures are required to prevent the spread of pox and prevent it from reaching pandemic status.

Conflict of interest: None declared
==== Refs
References

1 World Health Organization (WHO) News Release WHO Director-General declares mpox outbreak a public health emergency of international concern 14 August 2024 Available from:https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern
2 Kozlov M Growing mpox outbreak prompts WHO to declare global health emergency Nature 2024 632 8026 718 19 39143282
3 World Health Organization (WHO) News Mpox 17 August 2024 Available from:https://www.who.int/news-room/questions-and-answers/item/mpox#
4 World Health Organization (WHO) 2022-24 Mpox (monkeypox) outbreak: Global trends 22 August 2024 Available from:https://worldhealthorg.shinyapps.io/mpx_global/
5 Parums DV Editorial: Current Status of Non-Endemic Global Infections with the Monkeypox Virus Med Sci Monit 2022 28 e938203 36047039
6 Moore MJ Rathish B Zahra F Mpox (monkeypox) StatPearls [Internet] Treasure Island (FL) StatPearls Publishing 2024 Available from:https://www.ncbi.nlm.nih.gov/books/NBK574519/
7 Haque MA Halder AS Hossain MJ Islam MR Prediction of potential public health risk of the recent multicountry monkeypox outbreak: An update after the end declaration of global public health emergency Health Sci Rep 2024 7 6 e2136 38817885
8 Damon IK Status of human monkeypox: Clinical disease, epidemiology and research Vaccine 2011 29 D54 59 22185831
9 International Committee on Taxonomy of Viruses (ICTV) Poxviridae Available from:https://ictv.global/report/chapter/poxviridae/poxviridae#
10 Chen N Li G Liszewski MK Virulence differences between monkeypox virus isolates from West Africa and the Congo basin Virology 2005 340 1 46 63 16023693
11 Brown K Leggat PA Human monkeypox: Current state of knowledge and implications for the future Trop Med Infect Dis 2016 1 1 8 30270859
12 Morgan CN Whitehill F Doty JB Environmental persistence of monkeypox virus on surfaces in household of person with travel-associated infection, Dallas, Texas, USA, 2021 Emerg Infect Dis 2022 28 10 1982 89 35951009
13 Philpott D Hughes CM Alroy KA CDC Multinational Monkeypox Response Team Epidemiologic and clinical characteristics of monkeypox cases – United States, May 17–July 22, 2022 MMWR Morb Mortal Wkly Rep 2022 71 32 1018 22 35951487
14 European Centre for Disease Prevention and Control (ECDC) Factsheet for health professionals on mpox 22 August 2024 Available from:https://www.ecdc.europa.eu/en/all-topics-z/monkeypox/factsheet-health-professionals
15 Rana J Patel SK Agrawal A Mpox vaccination in global perspective: Priorities and challenges Ann Med Surg (Lond) 2023 85 5 2243 46 37228971
